BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
BriaCell presented ESMO 2026 biomarker findings showing dynamic changes in PD-L1 expression on circulating CAMLs were significantly associated with progression-free and overall survival in metastatic breast cancer patients treated with immunotherapies including Bria-IMT. The prospective pooled analysis covered 111 heavily pretreated patients; at ~3 months post-treatment, CAML PD-L1 was significantly associated with both PFS (HR=2.73; p=0.0028) and OS (HR=2.27; p=0.0420), while baseline measurements and tumor PD-L1 CPS were not predictive.
Key figures
- Drug Name
- Bria-IMT
- Phase Of Trial
- Phase 3
- Tnbc share
- 60%
- Caml pdl1 os T2
- HR=2.27; p=0.0420
- Caml pdl1 pfs T1
- HR=1.86; p=0.0276
- Caml pdl1 pfs T2
- HR=2.73; p=0.0028
- Patients analyzed
- 111
- Interim analysis trigger
- 144 patient deaths
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.